OncoMatch/Clinical Trials/NCT06462248
Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
Is NCT06462248 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies CUCART19 for lymphoma, nonhodgkin.
Treatment: CUCART19 — CAR-T therapy is now available as a commercial product for treatment of relapsed /refractory acute lymphoblastic leukaemia and B-lymphoma. There is limited access to this new treatment as the product is very expensive. It is imperative to develop cost effective, closed circuit manufacturing systems for CAR-T cells to make CAR-T cells a point-of care production option. Hong Kong Institute of Biotechnology has established a certified GMP facility and utilize the Prodigy system to manufacture CAR-T cells for clinical application. Prince of Wales Hospital and Hong Kong Children's Hospital will conduct the phase II clinical trial to confirm the efficacy and safety of local manufactured CAR-T cell product.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD19 positive
Required: CD19 positive
Performance status
ECOG/LANSKY 0–2
Demographics
Prior therapy
Must have received: intensive systemic therapy
Lab requirements
Kidney function
Creatinine clearance <50 mL/min/1.73 m2
Liver function
serum bilirubin >3 times upper limit of normal or an AST or ALT > 5 times upper limit of normal, unless due to leukaemic liver infiltration in the estimation of the investigator
Cardiac function
Fractional shortening <28% or left ventricular ejection fraction <45% by echocardiography
Pulmonary function: Grade 1 dyspnea and pulse oxygenation > 91% on room air; Cardiac function: Fractional shortening <28% or left ventricular ejection fraction <45% by echocardiography. Renal function: Creatinine clearance <50 mL/min/1.73 m2. Liver function: Patients with a serum bilirubin >3 times upper limit of normal or an AST or ALT > 5 times upper limit of normal, unless due to leukaemic liver infiltration in the estimation of the investigator
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06462248 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received intensive systemic therapy.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 60 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify